Literature DB >> 20579226

[S2k-guideline for therapy of acne].

Alexander Nast1, Christiane Bayerl, Claudia Borelli, Klaus Degitz, Thomas Dirschka, Ricardo Erdmann, Joachim Fluhr, Uwe Gieler, Roland Hartwig, Eva-Maria Meigel, Siegfried Möller, Falk Ochsendorf, Maurizio Podda, Thomas Rabe, Berthold Rzany, Adel Sammain, Susanne Schink, Christos C Zouboulis, Harald Gollnick.   

Abstract

To optimize the treatment of acne in Germany, the German Society of Dermatology (DDG) and the Association of German Dermatologists (BVDD) initiated a project to develop consensus-based guidelines for the management of acne. The Acne Guidelines focus on induction therapy, maintenance therapy and treatment of post-acne scarring. They include an evaluation of the most commonly used therapeutic options in Germany. In addition, they offer detailed information on how to administer the various treatments and on contraindications, adverse drug reactions, and drug interactions, taking into account gender and special conditions such as pregnancy and lactation. The Acne Guidelines were developed following the recommendations of the Association of Scientific Medical Societies in Germany (AWMF). The treatment recommendations were developed by an expert group and finalized by an interdisciplinary consensus conference. The first choice treatments for acute acne according to acne type are as follows: 1) comedonal acne: topical retinoids; 2) mild papular/pustular acne: fixed or sequential combinations of BPO and topical retinoids or of BPO and topical antibiotics; 3) moderate papular/pustular acne: oral antibiotic plus BPO or plus topical retinoid, or in a fixed combination 4) acne papulo-pustulosa nodosa and acne conglobata: oral antibiotic plus topical retinoid plus BPO or oral isotretinoin. For maintenance treatment: topical retinoid or its combination with BPO. Particular attention should be paid to compliance and quality of life. Additional treatment options are discussed in the main body of the text.

Entities:  

Mesh:

Year:  2010        PMID: 20579226     DOI: 10.1111/j.1610-0387.2010.07466.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  16 in total

Review 1.  [Dermatologic therapy in pregnancy].

Authors:  J Wohlrab
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

Review 2.  [Nonablative fractional lasers: Acne scars and other indications].

Authors:  K Degitz
Journal:  Hautarzt       Date:  2015-10       Impact factor: 0.751

Review 3.  [Photodynamic therapy-trends and new developments].

Authors:  R-M Szeimies; S Karrer
Journal:  Hautarzt       Date:  2020-12-10       Impact factor: 0.751

4.  [Pathophysiology of acne. What is confirmed?].

Authors:  C C Zouboulis
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

Review 5.  [Topical therapy of inflammatory dermatoses, pruritus and pain, as well as hyperhidrosis].

Authors:  K Schultheis; A Messerschmidt; F Ochsendorf
Journal:  Hautarzt       Date:  2014-03       Impact factor: 0.751

Review 6.  [Retinoids in dermatopharmacology].

Authors:  P M Amann; H F Merk; J M Baron
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

7.  Impact of Parallel Topical Treatment with Nadifloxacin and Adapalene on Acne Vulgaris Severity and Quality of Life: A Prospective, Uncontrolled, Multicentric, Noninterventional Study.

Authors:  Claudia Neumeister; Rolf-Hasso Bödeker; Ulrich Schwantes; Claudia Borelli
Journal:  Biomed Hub       Date:  2021-12-20

Review 8.  Not all acne is acne vulgaris.

Authors:  Harald P Gollnick; Christos C Zouboulis
Journal:  Dtsch Arztebl Int       Date:  2014-04-25       Impact factor: 5.594

9.  [Isotretinoin. How should it be used?].

Authors:  A Thielitz; H Gollnick
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

10.  Oral isotretinoin for acne.

Authors:  Caroline S Costa; Ediléia Bagatin; Ana Luiza C Martimbianco; Edina Mk da Silva; Marília M Lúcio; Parker Magin; Rachel Riera
Journal:  Cochrane Database Syst Rev       Date:  2018-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.